Androgen Receptor Pathway Inhibition In Metastatic Castration Resistant Prostate Cancer Therapeutics
1. Zytiga patent expiration
Treatment: Use in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer; Use in combination with prednisone for the treatment of patients with m...
ZYTIGA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822438 | JANSSEN BIOTECH | Methods and compositions for treating cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US5604213 | JANSSEN BIOTECH | 17-substituted steroids useful in cancer treatment |
Feb, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-663) | Dec 10, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2016 |
| New Indication(I-765) | Feb 07, 2021 |
Drugs and Companies using ABIRATERONE ACETATE ingredient
NCE-1 date: 29 April, 2015
Market Authorisation Date: 28 April, 2011
Dosage: TABLET
How can I launch a generic of ZYTIGA before it's drug patent expiration?
More Information on Dosage
ZYTIGA family patents
